Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-08-27 DOI:10.1016/j.bmc.2024.117896

Yi Du , Xiya Chen , Weiji Chen , Gang Chen , Xiaoling Cheng , Hailing Wang , Ling Guo , Chenyang Li , Dahong Yao

{"title":"Design, synthesis and biological evaluation of a novel PAK1 degrader for the treatment of triple negative breast cancer","authors":"Yi Du , Xiya Chen , Weiji Chen , Gang Chen , Xiaoling Cheng , Hailing Wang , Ling Guo , Chenyang Li , Dahong Yao","doi":"10.1016/j.bmc.2024.117896","DOIUrl":null,"url":null,"abstract":"<div>Triple-negative breast cancer is one of the most malignant subtypes in clinical practice, and it is urgent to find new therapies. The p21-activated kinase I (PAK1) has been considered to be an attractive therapeutic target for TNBC. In this study, we designed and synthesized a series of novel PROTAC PAK1 degraders by conjugating VHL or CRBN ligase ligands to PAK1 inhibitors which are connected by alkyl chains or PEG chains. The most promising compound, 19s, can significantly degrade PAK1 protein at concentrations as low as 0.1 μM, and achieves potent anti-proliferative activity with an IC50 value of 1.27 μM in MDA-MB-231 cells. Additionally, 19s exhibits potent anti-migration activity in vitro and induces rapid tumor regression in vivo. Collectively, these findings document that 19s is a potent and novel PAK1 degrader with promising potential for TNBC treatment.</div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0968089624003109","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 0

Abstract

Triple-negative breast cancer is one of the most malignant subtypes in clinical practice, and it is urgent to find new therapies. The p21-activated kinase I (PAK1) has been considered to be an attractive therapeutic target for TNBC. In this study, we designed and synthesized a series of novel PROTAC PAK1 degraders by conjugating VHL or CRBN ligase ligands to PAK1 inhibitors which are connected by alkyl chains or PEG chains. The most promising compound, 19s, can significantly degrade PAK1 protein at concentrations as low as 0.1 μM, and achieves potent anti-proliferative activity with an IC₅₀ value of 1.27 μM in MDA-MB-231 cells. Additionally, 19s exhibits potent anti-migration activity in vitro and induces rapid tumor regression in vivo. Collectively, these findings document that 19s is a potent and novel PAK1 degrader with promising potential for TNBC treatment.

Abstract Image

查看原文本刊更多论文

用于治疗三阴性乳腺癌的新型 PAK1 降解剂的设计、合成和生物学评价

三阴性乳腺癌是临床上恶性程度最高的亚型之一，迫切需要找到新的治疗方法。p21激活激酶I（PAK1）一直被认为是TNBC的一个有吸引力的治疗靶点。在这项研究中，我们通过将 VHL 或 CRBN 连接酶配体与 PAK1 抑制剂共轭，设计并合成了一系列新型 PROTAC PAK1 降解剂，这些配体由烷基链或 PEG 链连接。其中最有前景的化合物 19s 能在低至 0.1 μM 的浓度下显著降解 PAK1 蛋白，并在 MDA-MB-231 细胞中发挥强效抗增殖活性，IC50 值为 1.27 μM。此外，19s 还在体外表现出强大的抗迁移活性，并在体内诱导肿瘤快速消退。总之，这些研究结果证明 19s 是一种有效的新型 PAK1 降解剂，有望用于 TNBC 治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567